# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF inj...
- SEC Filing
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...
4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.